Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

  • End date
    Dec 26, 2021
  • participants needed
  • sponsor
    University of Minnesota
Updated on 26 January 2021


The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.

Condition Hyperbilirubinemia, Adenocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA, Liver Cancer, Malignant Adenoma, liver cell carcinoma, hyperbilirubinaemia
Treatment Transarterial Chemoembolization
Clinical Study IdentifierNCT03259581
SponsorUniversity of Minnesota
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: HEPATIC NEOPLASM or liver cell carcinoma or hyperbilirubinaemia or HEPATOCELLULAR CARCINOMA or Malignant Adenoma or Liver Cancer or Hyperbilirubinemia...?
Do you have any of these conditions: Adenocarcinoma or Hyperbilirubinemia or Malignant Adenoma or liver cell carcinoma or hyperbilirubinaemia or HEPATIC NEOPLASM or Liver Cancer or HEPATO...?
Do you have any of these conditions: Liver Cancer or Malignant Adenoma or HEPATOCELLULAR CARCINOMA or Adenocarcinoma or liver cell carcinoma or hyperbilirubinaemia or Hyperbilirubinemia o...?
hepatocellular carcinoma (HCC)
Direct or conjugated bilirubin < 3 mg/dl
Total bilirubin > 3 mg/dl
Willing and able to provide informed consent
>18 years of age

Exclusion Criteria

Currently pregnant
Patients who are surgical or ablation candidates as determined by multidisciplinary hepatobiliary tumor conference
Arterial anatomy which would preclude selective transarterial chemoembolization
Patients who have a INR or platelet count which are not correctable to <1.8 and >35,000 respectively
Patients with extrahepatic metastases
Patients with portal vein invasion
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note